In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List

3rd RAS/MAPK Pathway Targeted Drug Discovery Summit

Feb 22, 2022 - 09:00 AM - Feb 24, 03:30 PM
Hanson Wade
Hyatt Regency Boston
1 Avenue de Lafayette,

ZIP: 02111
Phone: +44 02031418700

Ticket Price: USD 2099.00 - USD 5396.00

For decades, RAS proteins have been considered “undruggable.” This all changed following the recent approval of the first-ever targeted KRAS G12C therapy, marking a major landmark for this community. This breakthrough has certainly laid out a roadmap for future success, with more investment and innovation in the field than ever before, particularly within emerging discovery strategies being pursued by the biopharma industry.

Along with this success, significant efforts are now being placed within discovery of drugs that treat a broader range of RAS mutants beyond G12C. The 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit, will shine a spotlight onto pioneering discovery effort targeting the RAS/MAPK pathway, and benchmark the various innovative modalities being harnessed to target RAS mutations beyond G12C, giving you the opportunity to establish and accelerate your drug discovery platform by targeting the RAS/MAPK pathway at every turn.

Tickets    https://go.evvnt.com/913421-2?pid=1052
Brochure https://go.evvnt.com/913421-3?pid=1052

Conference + Workshop Day - Drug Developer Pricing - Physical Attendance USD 4496.00
Conference Only - Drug Developer Pricing - Physical Attendance USD 2999.00
Conference + Workshop Day - Drug Developer Pricing - Digital Attendance USD 3146.00
Conference Only - Drug Developer Pricing - Digital Attendance USD 2099.00
Conference + Workshop Day - Standard Pricing - Physical Attendance USD 5396.00
Conference Only - Standard Pricing - Physical Attendance USD 3599.00
Conference + Workshop Day - Academic Pricing - Physical Attendance USD 3796.00
Conference Only - Academic Pricing - Physical Attendance USD 2599.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Speaker Details

Mallika Singh Vice President, Translational Research Revolution Medicine, Jack Sadowsky Principal Investigator of Discovery Chemistry Carmot Therapeutics, Jeffrey Rothman Assistant Professor, Columbia University Medical Center & CSO, Founder Oncogenuity, Iris Valtingojer Group Leader, Oncology Research Sanofi R&D, Hanna Budayeva Principal Scientific Researcher Genentech, Reagan Jarvis Chief Executive Officer Anocca, Andrea Gohlke Senior Biophysics Scientist AstraZeneca, Armon Sharei CEO & Founder SQZ Biotechnologies, Carmine Fedele Principal Scientist II, Oncology-Drug Discovery Novartis Institute of Biomedical Research, Marcel Frenkel Chief Executive Officer Ten63 Therapeutics, Jeff Ecsedy Chief Scientific Officer Ikena Oncology, Thomas Tibbitts Chief Executive Officer Dogodan Therapeutics, Poulikos Poulikakos Associate Professor Icahn School of Medicine at Mount Sinai, Frantz JeanFrancois Team Lead, RAS initiative Frederick National Laboratory for Cancer Research, Michael Eck Professor, Department of Biological Chemistry & Molecular Pharmacology Harvard Medical School, Raghu Kalluri Professor & Chair, Department of Cancer Biology The University of Texas MD Anderson Cancer Center, Siyuan Le Senior Director of Biology GenFleet Therapeutics, Greg Jones Senior Scientist & Team Leader Pfizer, Sreesha Srinivasa Chief Development Officer Oblique Therapeutics, Mark Hallen Chief Technology Officer Ten63 Therapeutics, Helen Mott Associate Professor, University of Cambridge, Erik Knelson Medical Oncologist Dana-Farber Cancer Institute, Trever Bivona, Professor, Hematology & Oncology, UCSF

Event Categories


Events Calendar

30 31 1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 1 2 3 4 5


VIP Life Time Subscription to our Newsletters!